Nanomedicine: Nanotechnology, Biology and Medicine
Volume 8, Issue 2 , Pages 147-166 , February 2012

Nanoparticles: a boon to drug delivery, therapeutics, diagnostics and imaging

Received 6 December 2010 ,Accepted 29 May 2011.

References 

  1. Orive G, Hernandez RM, Rodriguez Gascon A, Dominguez-Gil A, Pedraz JL. Drug delivery in biotechnology: present and future. Curr Opin Biotechnol. 2003;14:659–664
  2. Langer R. New methods of drug delivery. Science. 1990;249:1527–1533
  3. Juliano RL. Drug delivery systems: a brief review. Can J Physiol Pharmacol. 1978;56:683–690
  4. Parveen S, Sahoo SK. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Clin Pharmacokinet. 2006;45:965–988
  5. Lee HJ. Protein drug oral delivery: the recent progress. Arch Pharm Res. 2002;25:572–584
  6. Kayser O, Lemke A, Hernandez-Trejo N. The impact of nanobiotechnology on the development of new drug delivery systems. Curr Pharm Biotechnol. 2005;6:3–5
  7. Sahoo SK, Parveen S, Panda JJ. The present and future of nanotechnology in human health care. Nanomedicine. 2007;3:20–31
  8. Sahoo SK, Labhasetwar V. Nanotech approaches to drug delivery and imaging. Drug Discov Today. 2003;8:1112–1120
  9. Moghimi SM, Hunter AC, Murray JC. Nanomedicine: current status and future prospects. Faseb J. 2005;19:311–330
  10. Torchilin VP. Drug targeting. Eur J Pharm Sci. 2000;11(Suppl 2):S81–S91
  11. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–284
  12. Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46:6387–6392
  13. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71:409–419
  14. Gullotti E, Yeo Y. Extracellularly activated nanocarriers: a new paradigm of tumor targeted drug delivery. Mol Pharm. 2009;6:1041–1051
  15. Akao T, Kimura T, Hirofuji YS, Matsunaga K, Imayoshi R, Nagao JI, et al. A poly(gamma-glutamic acid)-amphiphile complex as a novel nanovehicle for drug delivery system. J Drug Target. 2010;
  16. Cho KJ, Moon HT, Park GE, Jeon OC, Byun Y, Lee YK. Preparation of sodium deoxycholate (DOC) conjugated heparin derivatives for inhibition of angiogenesis and cancer cell growth. Bioconjug Chem. 2008;19:1346–1351
  17. Chytil P, Etrych T, Konak C, Sirova M, Mrkvan T, Boucek J, et al. New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting. J Control Release. 2008;127:121–130
  18. Kim JH, Kim YS, Park K, Lee S, Nam HY, Min KH, et al. Antitumor efficacy of cisplatin-loaded glycol chitosan nanoparticles in tumor-bearing mice. J Control Release. 2008;127:41–49
  19. Sahoo SK, Ma W, Labhasetwar V. Efficacy of transferrin-conjugated paclitaxel-loaded nanoparticles in a murine model of prostate cancer. Int J Cancer. 2004;112:335–340
  20. Sahoo SK, Labhasetwar V. Enhanced antiproliferative activity of transferrin-conjugated paclitaxel-loaded nanoparticles is mediated via sustained intracellular drug retention. Mol Pharm. 2005;2:373–383
  21. Panyam J, Labhasetwar V. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev. 2003;55:329–347
  22. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res. 2004;10:415–427
  23. Molema G, Meijer DK, de Leij LF. Tumor vasculature targeted therapies: getting the players organized. Biochem Pharmacol. 1998;55:1939–1945
  24. Choi CH, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci U S A. 2010;107:1235–1240
  25. Kocbek P, Obermajer N, Cegnar M, Kos J, Kristl J. Targeting cancer cells using PLGA nanoparticles surface modified with monoclonal antibody. J Control Release. 2007;120:18–26
  26. Tong R, Yala L, Fan TM, Cheng J. The formulation of aptamer-coated paclitaxel-polylactide nanoconjugates and their targeting to cancer cells. Biomaterials. 2010;31:3043–3053
  27. Barraud L, Merle P, Soma E, Lefrançois L, Guerret S, Chevallier M, et al. Increase of doxorubicin sensitivity by doxorubicin-loading into nanoparticles for hepatocellular carcinoma cells in vitro and in vivo. J Hepatol. 2005;42:736–743
  28. Cheng FY, Su CH, Wu PC, Yeh CS. Multifunctional polymeric nanoparticles for combined chemotherapeutic and near-infrared photothermal cancer therapy in vitro and in vivo. Chem Commun (Camb). 2010;46:3167–3169
  29. Chithrani DB, Jelveh S, Jalali F, van Prooijen M, Allen C, Bristow RG, et al. Gold nanoparticles as radiation sensitizers in cancer therapy. Radiat Res. 2010;173:719–728
  30. Hee-Dong H, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen DY, et al. Targeted gene silencing using rgd-labeled chitosan nanoparticles. Clin Cancer Res. 2010;
  31. Koziara JM, Lockman PR, Allen DD, Mumper RJ. Paclitaxel nanoparticles for the potential treatment of brain tumors. J Control Release. 2004;99:259–269
  32. Lamprecht A, Benoit JP. Etoposide nanocarriers suppress glioma cell growth by intracellular drug delivery and simultaneous P-glycoprotein inhibition. J Control Release. 2006;112:208–213
  33. Ozay O, Akcali A, Otkun MT, Silan C, Aktas N, Sahiner N. P(4-VP) based nanoparticles and composites with dual action as antimicrobial materials. Colloids Surf B Biointerfaces. 2010;
  34. Parveen S, Mitra M, Krishnakumar S, Sahoo SK. Enhanced antiproliferative activity of carboplatin-loaded chitosan-alginate nanoparticles in a retinoblastoma cell line. Acta Biomater. 2010;6:3120–3131
  35. Zhang C, Zhao L, Dong Y, Zhang X, Lin J, Chen Z. Folate-mediated poly(3-hydroxybutyrate-co-3-hydroxyoctanoate) nanoparticles for targeting drug delivery. Eur J Pharm Biopharm. 2010;
  36. Medley CD, Smith JE, Tang Z, Wu Y, Bamrungsap S, Tan W. Gold nanoparticle-based colorimetric assay for the direct detection of cancerous cells. Anal Chem. 2008;80:1067–1072
  37. Corsi F, De Palma C, Colombo M, Allevi R, Nebuloni M, Ronchi S, et al. Towards ideal magnetofluorescent nanoparticles for bimodal detection of breast-cancer cells. Small. 2009;5:2555–2564
  38. de la Escosura-Muñiz A, Sánchez-Espinel C, Díaz-Freitas B, González-Fernández A, Maltez-da Costa M, Merkoçi A. Rapid identification and quantification of tumor cells using an electrocatalytic method based on gold nanoparticles. Anal Chem. 2009;81:10268–10274
  39. Farias PM, Santos BS, Fontes A. Semiconductor fluorescent quantum dots: efficient biolabels in cancer diagnostics. Methods Mol Biol. 2009;544:407–419
  40. Smith AM, Dave S, Nie S, True L, Gao X. Multicolor quantum dots for molecular diagnostics of cancer. Expert Rev Mol Diagn. 2006;6:231–244
  41. Smith JE, Medley CD, Tang Z, Shangguan D, Lofton C, Tan W. Aptamer-conjugated nanoparticles for the collection and detection of multiple cancer cells. Anal Chem. 2007;79:3075–3082
  42. Valanne A, Huopalahti S, Soukka T, Vainionpää R, Lövgren T, Härmä H. A sensitive adenovirus immunoassay as a model for using nanoparticle label technology in virus diagnostics.. J Clin Virol. 2005;33:217–223
  43. Brambilla D, Nicolas J, Le Droumaguet B, Andrieux K, Marsaud V, Couraud PO, et al. Design of fluorescently tagged poly(alkyl cyanoacrylate) nanoparticles for human brain endothelial cell imaging. Chem Commun (Camb). 2010;46:2602–2604
  44. Craig GA, Allen PJ, Mason MD. Synthesis, characterization, and functionalization of gold nanoparticles for cancer imaging. Methods Mol Biol. 2010;624:177–193
  45. Kim D, Jeong YY, Jon S. A Drug-Loaded Aptamer-Gold Nanoparticle Bioconjugate for Combined CT Imaging and Therapy of Prostate Cancer. ACS Nano. 2010;
  46. Liang M, Liu X, Cheng D, Liu G, Dou S, Wang Y, et al. Multimodality Nuclear and Fluorescence Tumor Imaging in Mice Using a Streptavidin Nanoparticle. Bioconjug Chem. 2010;
  47. Maeng JH, Lee DH, Jung KH, Bae YH, Park IS, Jeong S, et al Multifunctional doxorubicin loaded superparamagnetic iron oxide nanoparticles for chemotherapy and magnetic resonance imaging in liver cancer. Biomaterials. 2010;31:4995–5006
  48. Nam T, Park S, Lee SY, Park K, Choi K, Song IC, et al Tumor targeting chitosan nanoparticles for dual-modality optical/MR cancer imaging. Bioconjug Chem. 2010;21:578–582
  49. Nurunnabi M, Cho KJ, Choi JS, Huh KM, Lee YK. Targeted near-IR QDs-loaded micelles for cancer therapy and imaging. Biomaterials. 2010;31:5436–5444
  50. Qian J, Wang Y, Gao X, Zhan Q, Xu Z, He S. Carboxyl-functionalized and bio-conjugated silica-coated quantum dots as targeting probes for cell imaging. J Nanosci Nanotechnol. 2010;10
  51. Santra S. Fluorescent silica nanoparticles for cancer imaging. Methods Mol Biol. 2010;624:151–162
  52. Tang F, He F, Cheng H, Li L. Self-assembly of conjugated polymer-ag@sio(2) hybrid fluorescent nanoparticles for application to cellular imaging. Langmuir. 2010;
  53. Parveen S, Sahoo SK. Polymeric nanoparticles for cancer therapy. J Drug Target. 2008;16:108–123
  54. Yih TC, Al-Fandi M. Engineered nanoparticles as precise drug delivery systems. J Cell Biochem. 2006;97:1184–1190
  55. Dutta N, Green D. Nanoparticle stability in semidilute and concentrated polymer solutions. Langmuir. 2008;24:5260–5269
  56. Panyam J, Sahoo SK, Prabha S, Bargar T, Labhasetwar V. Fluorescence and electron microscopy probes for cellular and tissue uptake of poly(D,L-lactide-co-glycolide) nanoparticles. Int J Pharm. 2003;262:1–11
  57. Panyam J, Zhou WZ, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: implications for drug and gene delivery. Faseb J. 2002;16:1217–1226
  58. Yang H, Li K, Liu Y, Liu Z, Miyoshi H. Poly(D,L-lactide-co-glycolide) nanoparticles encapsulated fluorescent isothiocyanate and paclitaxol: preparation, release kinetics and anticancer effect. J Nanosci Nanotechnol. 2009;9:282–287
  59. Fadel M, Kassab K, Fadeel DA. Zinc phthalocyanine-loaded PLGA biodegradable nanoparticles for photodynamic therapy in tumor-bearing mice. Lasers Med Sci. 2010;25:283–292
  60. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. Adv Drug Deliv Rev. 2002;54:631–651
  61. Vauthier C, Dubernet C, Chauvierre C, Brigger I, Couvreur P. Drug delivery to resistant tumors: the potential of poly(alkyl cyanoacrylate) nanoparticles. J Control Release. 2003;93:151–160
  62. Song XR, Cai Z, Zheng Y, He G, Cui FY, Gong DQ, et al. Reversion of multidrug resistance by co-encapsulation of vincristine and verapamil in PLGA nanoparticles. Eur J Pharm Sci. 2009;37:300–305
  63. Wang J, Tao X, Zhang Y, Wei D, Ren Y. Reversion of multidrug resistance by tumor targeted delivery of antisense oligodeoxynucleotides in hydroxypropyl-chitosan nanoparticles. Biomaterials. 2010;31:4426–4433
  64. Fisher RS, Ho J. Potential new methods for antiepileptic drug delivery. CNS Drugs. 2002;16:579–593
  65. Lockman PR, Mumper RJ, Khan MA, Allen DD. Nanoparticle technology for drug delivery across the blood-brain barrier. Drug Dev Ind Pharm. 2002;28:1–13
  66. Sun H, Dai H, Shaik N, Elmquist WF. Drug efflux transporters in the CNS. Adv Drug Deliv Rev. 2003;55:83–105
  67. Kreuter J, Ramge P, Petrov V, Hamm S, Gelperina SE, Engelhardt B, et al. Direct evidence that polysorbate-80-coated poly(butylcyanoacrylate) nanoparticles deliver drugs to the CNS via specific mechanisms requiring prior binding of drug to the nanoparticles. Pharm Res. 2003;20:409–416
  68. Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther. 2003;14:1–12
  69. Wang ZH, Wang ZY, Sun CS, Wang CY, Jiang TY, Wang SL. Trimethylated chitosan-conjugated PLGA nanoparticles for the delivery of drugs to the brain. Biomaterials. 2010;31:908–915
  70. Andersen MO, Lichawska A, Arpanaei A, Rask Jensen SM, Kaur H, Oupicky D, et al. Surface functionalisation of PLGA nanoparticles for gene silencing. Biomaterials. 2010;31:5671–5677
  71. Sahu SK, Maiti S, Maiti TK, Ghosh SK, Pramanik P. Hydrophobically modified carboxymethyl chitosan nanoparticles targeted delivery of paclitaxel. J Drug Target. 2010;
  72. Muller RH, Ruhl D, Runge S, Schulze-Forster K, Mehnert W. Cytotoxicity of solid lipid nanoparticles as a function of the lipid matrix and the surfactant. Pharm Res. 1997;14:458–462
  73. Cavalli R, Gasco MR, Chetoni P, Burgalassi S, Saettone MF. Solid lipid nanoparticles (SLN) as ocular delivery system for tobramycin. Int J Pharm. 2002;238:241–245
  74. Yang SC, Lu LF, Cai Y, Zhu JB, Liang BW, Yang CZ. Body distribution in mice of intravenously injected camptothecin solid lipid nanoparticles and targeting effect on brain. J Control Release. 1999;59:299–307
  75. Wissing SA, Kayser O, Muller RH. Solid lipid nanoparticles for parenteral drug delivery. Adv Drug Deliv Rev. 2004;56:1257–1272
  76. Fundaro A, Cavalli R, Bargoni A, Vighetto D, Zara GP, Gasco MR. Non-stealth and stealth solid lipid nanoparticles (SLN) carrying doxorubicin: pharmacokinetics and tissue distribution after i.v. administration to rats. Pharmacol Res. 2000;42:337–343
  77. Maia CS, Mehnert W, Schafer-Korting M. Solid lipid nanoparticles as drug carriers for topical glucocorticoids. Int J Pharm. 2000;196:165–167
  78. Uner M, Wissing SA, Yener G, Muller RH. Influence of surfactants on the physical stability of solid lipid nanoparticle (SLN) formulations. Pharmazie. 2004;59:331–332
  79. Zara GP, Cavalli R, Bargoni A, Fundaro A, Vighetto D, Gasco MR. Intravenous administration to rabbits of non-stealth and stealth doxorubicin-loaded solid lipid nanoparticles at increasing concentrations of stealth agent: pharmacokinetics and distribution of doxorubicin in brain and other tissues. J Drug Target. 2002;10:327–335
  80. Yu W, Liu C, Liu Y, Zhang N, Xu W. Mannan-modified solid lipid nanoparticles for targeted gene delivery to alveolar macrophages. Pharm Res. 2010;
  81. Jain TK, Roy I, De TK, Maitra AN. Nanometer silica particles encapsulating active compounds: a novel ceramic drug carrier. J Am Chem Soc. 1998;120:11092–11095
  82. Gref R, Minamitake Y, Peracchia MT, Trubetskoy V, Torchilin V, Langer R. Biodegradable long-circulating polymeric nanospheres. Science. 1994;263:1600–1603
  83. Lal M, Levy L, Kim KS, He GS, Wang X, Min YH, et al. silica nanobubbles containing an organic dye in a multilayered organic/inorganic heterostructure with enhanced luminescence. Chem Mater. 2000;19:2632–2639
  84. Badley RD, Ford WT, McEnroe FJ, Assink RA. Surface modification of colloidal silica. Langmuir. 1990;6:792–801
  85. Li Z, Zhu S, Gan K, Zhang Q, Zeng Z, Zhou Y, et al. Poly-L-lysine-modified silica nanoparticles: a potential oral gene delivery system. J Nanosci Nanotechnol. 2005;5:1199–1203
  86. Roy I, Ohulchanskyy TY, Pudavar HE, Bergey EJ, Oseroff AR, Morgan J, et al. Ceramic-based nanoparticles entrapping water-insoluble photosensitizing anticancer drugs: a novel drug-carrier system for photodynamic therapy. J Am Chem Soc. 2003;125:7860–7865
  87. Roy I, Ohulchanskyy TY, Bharali DJ, Pudavar HE, Mistretta RA, Kaur N, et al. Optical tracking of organically modified silica nanoparticles as DNA carriers: a nonviral, nanomedicine approach for gene delivery. Proc Natl Acad Sci U S A. 2005;102:279–284
  88. Mishra M, Kumar H, Tripathi K. Diabetic delayed wound healing and the role of silver nanoparticles. Digest Journal of Nanomaterials and Biostructures. 2008;3:49
  89. Becker S, Soukup JM, Gallagher JE. Differential particulate air pollution induced oxidant stress in human granulocytes, monocytes and alveolar macrophages. Toxicol In Vitro. 2002;16:209–218
  90. Schubert D, Dargusch R, Raitano J, Chan SW. Cerium and yttrium oxide nanoparticles are neuroprotective. Biochem Biophys Res Commun. 2006;342:86–91
  91. Bharali DJ, Klejbor I, Stachowiak EK, Dutta P, Roy I, Kaur N, et al. Organically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain. Proc Natl Acad Sci U S A. 2005;102:11539–11544
  92. Liu H, Webster TJ. Mechanical properties of dispersed ceramic nanoparticles in polymer composites for orthopedic applications. Int J Nanomedicine. 2010;5:299–313
  93. Dobson J. Magnetic micro- and nano-particle-based targeting for drug and gene delivery. Nanomedicine (Lond). 2006;1:31–37
  94. Gupta AK, Gupta M. Synthesis and surface engineering of iron oxide nanoparticles for biomedical applications. Biomaterials. 2005;26:3995–4021
  95. Dilnawaz F, Singh A, Mohanty C, Sahoo SK. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials. 2010;31:3694–3706
  96. Sahoo Y, Pizem H, Fried T, Golodnitsky D, Burstein L, Sukenik CN, et al. Alkyl phosphonate/phosphate coating on magnetite nanoparticles: a comparison with fatty acids. Langmuir. Biomaterials. 2001;17:7907–7911
  97. Zhang Y, Kohler N, Zhang M. Surface modification of superparamagnetic magnetite nanoparticles and their intracellular uptake. Biomaterials. 2002;23:1553–1561
  98. Chouly C, Pouliquen D, Lucet I, Jeune JJ, Jallet P. Development of superparamagnetic nanoparticles for MRI: effect of particle size, charge and surface nature on biodistribution. J Microencapsul. 1996;13:245–255
  99. Chatterjee J, Haik Y, Chen CJ. Modification and characterization of polystyrene-based magnetic microspheres and comparison with albumin-based magnetic microspheres. Journal of Magnetism and Magnetic Materials. 2001;225:21–29
  100. Kumar A, Sahoo B, Montpetit A, Behera S, Lockey RF, Mohapatra SS. Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides. Nanomedicine. 2007;3:132–137
  101. Liu X, Kaminski MD, Chen H, Torno M, Taylor L, Rosengart AJ. Synthesis and characterization of highly-magnetic biodegradable poly(d,l-lactide-co-glycolide) nanospheres. J Control Release. 2007;119:52–58
  102. Jain TK, Morales MA, Sahoo SK, Leslie-Pelecky DL, Labhasetwar V. Iron-oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm. 2005;
  103. Chertok B, David AE, Yang VC. Polyethyleneimine-modified iron oxide nanoparticles for brain tumor drug delivery using magnetic targeting and intra-carotid administration. Biomaterials. 2010;31:6317–6324
  104. Si HY, Li DP, Wang TM, Zhang HL, Ren FY, Xu ZG, et al. Improving the anti-tumor effect of genistein with a biocompatible superparamagnetic drug delivery system. J Nanosci Nanotechnol. 2010;10:2325–2331
  105. Sarin H, Kanevsky AS, Wu H, Brimacombe KR, Fung SH, Sousa AA, et al Effective transvascular delivery of nanoparticles across the blood-brain tumor barrier into malignant glioma cells. J Transl Med. 2008;6:80
  106. Bhattacharya R, Patra CR, Earl A, Wang S, Katarya A, Lu L, et al. Attaching folic acid on gold nanoparticles using noncovalent interaction via different polyethylene glycol backbones and targeting of cancer cells. Nanomed Nanotechnol Biol Med. 2007;3:224–238
  107. Hainfeld JF, Slatkin DN, Focella TM, Smilowitz HM. Gold nanoparticles: a new X-ray contrast agent. Br J Radiol. 2006;79:248–253
  108. Joshi HM, Bhumkar DR, Joshi K, Pokharkar V, Sastry M. Gold nanoparticles as carriers for efficient transmucosal insulin delivery. Langmuir. 2006;22:300–305
  109. Hosta-Rigau L, Olmedo I, Arbiol J, Cruz LJ, Kogan MJ, Albericio F. Multifunctionalized gold nanoparticles with peptides targeted to gastrin-releasing Peptide receptor of a tumor cell line. Bioconjug Chem. 2010;21:1070–1078
  110. Brown SD, Nativo P, Smith JA, Stirling D, Edwards PR, Venugopal B, et al. Gold nanoparticles for the improved anticancer drug delivery of the active component of oxaliplatin. J Am Chem Soc. 2010;132:4678–4684
  111. Li J, Wang X, Wang C, Chen B, Dai Y, Zhang R, et al. The enhancement effect of gold nanoparticles in drug delivery and as biomarkers of drug-resistant cancer cells. ChemMedChem. 2007;2:374–378
  112. Choi SJ, Oh JM, Choy JH. Biocompatible nanoparticles intercalated with anticancer drug for target delivery: pharmacokinetic and biodistribution study. J Nanosci Nanotechnol. 2010;10:2913–2916
  113. Tian J, Wong KK, Ho CM, Lok CN, Yu WY, Che CM, et al. Topical delivery of silver nanoparticles promotes wound healing. Chem Med Chem. 2007;2:129–136
  114. Song YY, Schmidt-Stein F, Bauer S, Schmuki P. Amphiphilic TiO2 nanotube arrays: an actively controllable drug delivery system. J Am Chem Soc. 2009;131:4230–4232
  115. Torchilin VP. Targeted polymeric micelles for delivery of poorly soluble drugs. Cell Mol Life Sci. 2004;61:2549–2559
  116. Torchilin VP, Trubetskoy VS, Whiteman KR, Caliceti P, Ferruti P, Veronese FM. New synthetic amphiphilic polymers for steric protection of liposomes in vivo. J Pharm Sci. 1995;84:1049–1053
  117. Jones M, Leroux J. Polymeric micelles - a new generation of colloidal drug carriers. Eur J Pharm Biopharm. 1999;48:101–111
  118. Allen C, Maysinger D, Eisenberg A. Nano-engineering block copolymer aggregates for drug delivery. Coll Surf B Biointerf. 1999;16:1–35
  119. Lin SY, Kawashima Y. Pluronic surfactants affecting diazepam solubility, compatibility, and adsorption from i.v. admixture solutions. J Parenter Sci Technol. 1987;41:83–87
  120. Lin SY, Kawashima Y. The influence of three poly(oxyethylene)poly(oxypropylene) surface-active block copolymers on the solubility behavior of indomethacin. Pharm Acta Helv. 1985;60:339–344
  121. Yokoyama M, Miyauchi M, Yamada N, Okano T, Sakurai Y, Kataoka K, et al. Characterization and anticancer activity of the micelle-forming polymeric anticancer drug adriamycin-conjugated poly(ethylene glycol)-poly(aspartic acid) block copolymer. Cancer Res. 1990;50:1693–1700
  122. Batrakova EV, Dorodnych TY, Klinskii EY, Kliushnenkova EN, Shemchukova OB, Goncharova ON, et al. Anthracycline antibiotics non-covalently incorporated into the block copolymer micelles: in vivo evaluation of anti-cancer activity. Br J Cancer. 1996;74:1545–1552
  123. Kabanov AV, Vinogradov SV, Suzdaltseva YG, Alakhov V. Water-soluble block polycations as carriers for oligonucleotide delivery. Bioconjug Chem. 1995;6:639–643
  124. Matsumura Y, Yokoyama M, Kataoka K, Okano T, Sakurai Y, Kawaguchi T, et al. Reduction of the side effects of an antitumor agent, KRN5500, by incorporation of the drug into polymeric micelles. Jpn J Cancer Res. 1999;90:122–128
  125. Allen C, Han J, Yu Y, Maysinger D, Eisenberg A. Polycaprolactone-b-poly(ethylene oxide) copolymer micelles as a delivery vehicle for dihydrotestosterone. J Control Release. 2000;63:275–286
  126. Yokoyama M, Okano T, Sakurai Y, Ekimoto H, Shibazaki C, Kataoka K. Toxicity and antitumor activity against solid tumors of micelle-forming polymeric anticancer drug and its extremely long circulation in blood. Cancer Res. 1991;51:3229–3236
  127. Trubetskoy VS, Torchilin VP. Polyethylene glycol based micelles as carriers of therapeutic and diagnostic agents. S T P Pharma Sci. 1996;6:79–86
  128. Weissig V, Whiteman KR, Torchilin VP. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm Res. 1998;15:1552–1556
  129. Lukyanov AN, Hartner WC, Torchilin VP. Increased accumulation of PEG-PE micelles in the area of experimental myocardial infarction in rabbits. J Control Release. 2004;94:187–193
  130. Kohori F, Sakai K, Aoyagi T, Yokoyama M, Sakurai Y, Okano T. Preparation and characterization of thermally responsive block copolymer micelles comprising poly(N-isopropylacrylamide-b-DL-lactide). J Control Release. 1998;55:87–98
  131. Le Garrec D, Taillefer J, Van Lier JE, Lenaerts V, Leroux JC. Optimizing pH-responsive polymeric micelles for drug delivery in a cancer photodynamic therapy model. J Drug Target. 2002;10:429–437
  132. Yoo HS, Lee EA, Park TG. Doxorubicin-conjugated biodegradable polymeric micelles having acid-cleavable linkages. J Control Release. 2002;82:17–27
  133. Vinogradov S, Batrakova E, Li S, Kabanov A. Polyion complex micelles with protein-modified corona for receptor-mediated delivery of oligonucleotides into cells. Bioconjug Chem. 1999;10:851–860
  134. Lee ES, Na K, Bae YH. Polymeric micelle for tumor pH and folate-mediated targeting. J Control Release. 2003;91:103–113
  135. Torchilin VP. Structure and design of polymeric surfactant-based drug delivery systems. J Control Release. 2001;73:137–172
  136. Lavasanifar A, Samuel J, Sattari S, Kwon GS. Block copolymer micelles for the encapsulation and delivery of amphotericin B. Pharm Res. 2002;19:418–422
  137. Wang Y, Yang T, Wang X, Wang J, Zhang X, Zhang Q. Targeted polymeric micelle system for delivery of combretastatin A4 to tumor vasculature in vitro. Pharm Res. 2010;
  138. Wang T, Petrenko VA, Torchilin VP. Paclitaxel-loaded polymeric micelles modified with MCF-7 cell-specific phage protein: enhanced binding to target cancer cells and increased cytotoxicity. Mol Pharm. 2010;
  139. Turnbull WB, Stoddart JF. Design and synthesis of glycodendrimers. J Biotechnol. 2002;90:231–255
  140. Li Y, Tseng YD, Kwon SY, D'Espaux L, Bunch JS, McEuen PL, et al. Controlled assembly of dendrimer-like DNA. Nat Mater. 2004;3:38–42
  141. Liu M, Kono K, Frechet JM. Water-soluble dendritic unimolecular micelles: their potential as drug delivery agents. J Control Release. 2000;65:121–131
  142. Malik N, Evagorou EG, Duncan R. Dendrimer-platinate: a novel approach to cancer chemotherapy. Anticancer Drugs. 1999;10:767–776
  143. Kukowska-Latallo JF, Candido KA, Cao Z, Nigavekar SS, Majoros IJ, Thomas TP, et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res. 2005;65:5317–5324
  144. Bhadra D, Bhadra S, Jain S, Jain NK. A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int J Pharm. 2003;257:111–124
  145. Wathier M, Jung PJ, Carnahan MA, Kim T, Grinstaff MW. Dendritic macromers as in situ polymerizing biomaterials for securing cataract incisions. J Am Chem Soc. 2004;126:12744–12745
  146. Grinstaff MW. Biodendrimers: new polymeric biomaterials for tissue engineering. Chemistry. 2002;8:2839–2846
  147. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M. Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int J Pharm. 2003;259:143–160
  148. El-Sayed M, Rhodes CA, Ginski M, Ghandehari H. Transport mechanism(s) of poly (amidoamine) dendrimers across Caco-2 cell monolayers. Int J Pharm. 2003;265:151–157
  149. Yao W, Sun K, Mu H, Liang N, Liu Y, Yao C, et al. Preparation and characterization of puerarin-dendrimer complexes as an ocular drug delivery system. Drug Dev Ind Pharm. 2010;
  150. Yuan H, Luo K, Lai Y, Pu Y, He B, Wang G, et al. A novel poly(l-glutamic acid) dendrimer based drug delivery system with both pH-sensitive and targeting functions. Mol Pharm. 2010;
  151. Sato N, Kobayashi H, Saga T, Nakamoto Y, Ishimori T, Togashi K, et al. Tumor targeting and imaging of intraperitoneal tumors by use of antisense oligo-DNA complexed with dendrimers and/or avidin in mice. Clin Cancer Res. 2001;7:3606–3612
  152. Arima H, Kihara F, Hirayama F, Uekama K. Enhancement of gene expression by polyamidoamine dendrimer conjugates with alpha-, beta-, and gamma-cyclodextrins. Bioconjug Chem. 2001;12:476–484
  153. Luo D, Haverstick K, Belcheva N, Han E, Saltzman WM. Poly(ethylene glycol)-conjugated PAMAM dendrimer for biocompatible high-efficiency DNA delivery. Macromolecules. 2002;35:3456–3462
  154. Gillies ER, Frechet JM. Designing macromolecules for therapeutic applications: polyester dendrimer-poly(ethylene oxide) "bow-tie" hybrids with tunable molecular weight and architecture. J Am Chem Soc. 2002;124:14137–14146
  155. Khopade AJ, Caruso F. Stepwise self-assembled poly(amidoamine) dendrimer and poly(styrenesulfonate) microcapsules as sustained delivery vehicles. Biomacromolecules. 2002;3:1154–1162
  156. Ofek P, Fischer W, Calderón M, Haag R, Satchi-Fainaro R. In vivo delivery of small interfering RNA to tumors and their vasculature by novel dendritic nanocarriers. FASEB J. 2010;
  157. Dutta T, Burgess M, McMillan NA, Parekh HS. Dendrosome-based delivery of siRNA against E6 and E7 oncogenes in cervical cancer. Nanomedicine. 2010;6:463–470
  158. Fadeel B, Garcia-Bennett AE. Better safe than sorry: Understanding the toxicological properties of inorganic nanoparticles manufactured for biomedical applications. Adv Drug Deliv Rev. 2010;62:362–374
  159. Kunzmann A, Andersson B, Thurnherr T, Krug H, Scheynius A, Fadeel B. Toxicology of engineered nanomaterials: focus on biocompatibility, biodistribution and biodegradation. Biochim Biophys Acta. 1810;2011:361–373
  160. De Jong WH, Borm PJ. Drug delivery and nanoparticles:applications and hazards. Int J Nanomedicine. 2008;3:133–149
  161. Radomski A, Jurasz P, Alonso-Escolano D, Drews M, Morandi M, Malinski T, et al. Nanoparticle-induced platelet aggregation and vascular thrombosis. Br J Pharmacol. 2005;146:882–893
  162. Lovern SB, Klaper R. Daphnia magna mortality when exposed to titanium dioxide and fullerene (C60) nanoparticles. Environ Toxicol Chem. 2006;25:1132–1137
  163. Yamakoshi Y, Umezawa N, Ryu A, Arakane K, Miyata N, Goda Y, et al. Active oxygen species generated from photoexcited fullerene (C60) as potential medicines: O2-⁎ versus 1O2. J Am Chem Soc. 2003;125:12803–12809
  164. Choi AO, Cho SJ, Desbarats J, Lovric J, Maysinger D. Quantum dot-induced cell death involves Fas upregulation and lipid peroxidation in human neuroblastoma cells. J Nanobiotechnology. 2007;5:1
  165. Cho SJ, Maysinger D, Jain M, Roder B, Hackbarth S, Winnik FM. Long-term exposure to CdTe quantum dots causes functional impairments in live cells. Langmuir. 2007;23:1974–1980
  166. Lin W, Huang YW, Zhou XD, Ma Y. In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicol Appl Pharmacol. 2006;217:252–259
  167. Chang JS, Chang KL, Hwang DF, Kong ZL. In vitro cytotoxicitiy of silica nanoparticles at high concentrations strongly depends on the metabolic activity type of the cell line. Environ Sci Technol. 2007;41:2064–2068
  168. Morimoto Y, Kobayashi N, Shinohara N, Myojo T, Tanaka I, Nakanishi J. Hazard assessments of manufactured nanomaterials. J Occup Health. 2010;52:325–334

 No conflict of interest was reported by the authors of this article.

 The Department of Biotechnology of Institute of Life Sciences, Nalco Square, Chandrasekharpur, Bhubaneswar, India, was a source of support for research.

PII: S1549-9634(11)00188-2

doi: 10.1016/j.nano.2011.05.016

Nanomedicine: Nanotechnology, Biology and Medicine
Volume 8, Issue 2 , Pages 147-166 , February 2012

Article Tools

* Image Usage & Resolution